BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter ...

Despite formidable competition in the growing transthyretin amyloid cardiomyopathy (ATTR-CM) market, a strong early launch ...

(Reuters) -U.S. drugmaker Pfizer reported first-quarter profit above Wall Street estimates on Tuesday, helped by cots cuts ...

Pfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its first quarter on the market and looks set to quickly enter blockbuster territory.

Pfizer reported first-quarter 2025 earnings on Tuesday that beat Wall Street expectations, boosted by ongoing cost-cutting ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...

It reported total revenue of $13.70 billion for the first quarter, compared with analysts' expectations of $13.91 billion, ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

(Find the latest earnings estimates and surprises on Zacks Earnings Calendar.) Revenues of products like Vyndaqel, Padcev, Lorbrena and BioNTech BNTX-partnered Comirnaty vaccine rose in the quarter.